If the FDA had concerns about elements of the data then they would typically call an Advisory Committee together to seek advice/clarification around those outstanding inquiries. It seems to me that it speaks to the thoroughness of Acadia's submission, but it most certainly was supported by the work done a couple of months ago with parent forums and the input of the various leading Rett organizations. I can only see this as a very good statement.
Ann: Rett Syndrome NDA accepted for Priority Review by FDA, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.76 |
Change
0.170(1.17%) |
Mkt cap ! $1.837B | |||
| Open | High | Low | Value | Volume |
| $14.36 | $14.86 | $14.25 | $3.707M | 254.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2500 | $14.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.80 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 16/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |